2024 ESMO Congress study: Haloperidol and lorazepam combination effectively reduces agitated delirium symptoms in advanced cancer patients.

A study from The University of Texas MD Anderson Cancer Center reveals that combining haloperidol and lorazepam effectively alleviates symptoms of agitated delirium in advanced cancer patients. Presented at the 2024 ESMO Congress, the RECORD trial involved 75 patients and found significant symptom reduction within 24 hours with minimal rescue doses, highlighting the benefits of tailored treatments in palliative care for improving end-of-life comfort.